肺类癌与大细胞神经内分泌癌的分子特征及其临床管理影响
本文综述肺类癌与大细胞神经内分泌癌(LCNEC)的分子特征研究进展。类癌突变负荷低、以染色质重塑基因(如MEN1)突变为主;LCNEC突变负荷高,可分为TP53/RB1双等位失活(SCLC特征)与TP53/STK11或KEAP1双等位失活(NSCLC特征)两个分子亚型。分子分型可能预测化疗反应,但需随机前瞻性试验验证。
要点
- 类癌突变负荷低,突变多集中于MEN1等染色质重塑基因。
- LCNEC可分TP53/RB1与TP53/STK11或KEAP1两类分子亚型。
- LCNEC分子亚型对化疗反应的预测价值尚待随机前瞻性试验验证。
核心结论
- 类癌与LCNEC具有不同的分子特征,LCNEC的两个分子亚型可能对化疗反应有预测价值,但尚需随机前瞻性临床试验验证。
- 未来应探索类癌中mTOR通路突变与mTOR抑制剂疗效的关联。
- DLL3抑制剂与免疫治疗可能为LCNEC提供个体化治疗选择。
研究设计与样本
- 本文为综述,汇总类癌与LCNEC分子特征的最新研究数据。
主要发现
- 类癌一般突变负荷低、反复突变基因少,多数突变位于染色质重塑基因(如MEN1),少数累及PI3K-AKT-mTOR通路基因。
- 侵袭性疾病与染色体碎裂、DNA修复基因突变、OTP/CD44缺失及RET表达上调相关。
- LCNEC突变负荷高,已识别两个主要分子亚型:TP53与RB1双等位失活(SCLC标志)及TP53与STK11/KEAP1双等位失活(NSCLC常见突变)。
- 复合性LCNEC各成分共享突变,提示LCNEC与其他肺肿瘤类型分子关系密切。
临床怎么用
- 类癌可关注mTOR通路突变与mTOR抑制剂疗效的关联研究。
- LCNEC可依据TP53/RB1与TP53/STK11或KEAP1分子亚型探索化疗反应预测。
- DLL3抑制剂与免疫治疗可作为LCNEC个体化治疗的候选方向。
局限性
- LCNEC分子亚型对化疗反应的预测价值仅为初步数据,尚需随机前瞻性临床试验验证。
- 类癌中mTOR通路突变与mTOR抑制剂疗效的关联仍需未来研究探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carcinoids and large cell neuroendocrine carcinomas (LCNECs) are rare neuroendocrine lung tumors. Here we provide an overview of the most updated data on the molecular characteristics of these diseases. Recent genomic studies showed that carcinoids generally contain a low mutational burden and few recurrently mutated genes. Most of the reported mutations occur in chromatin-remodeling genes (e.g., menin 1 gene [MEN1]), and few affect genes of the phosphoinositide 3-kinase (PI3K)-AKT-mechanistic target of rapamycin gene pathway. Aggressive disease has been related to chromothripsis, DNA-repair gene mutations, loss of orthopedia homeobox/CD44, and upregulation of ret proto-oncogene gene (RET) gene expression. In the case of LCNECs, which present with a high mutation burden, two major molecular subtypes have been identified: one with biallelic inactivation of tumor protein p53 gene (TP53) and retinoblastoma gene (RB1), a hallmark of SCLC; and the other one with biallelic inactivation of TP53 and serine/threonine kinase 11 gene (STK11)/kelch like ECH associated protein 1 gene (KEAP1), genes that are frequently mutated in NSCLC. These data, together with the identification of common mutations in the different components of combined LCNEC tumors, provide further evidence of the close molecular relation of LCNEC with other lung tumor types. In terms of therapeutic options, future studies should explore the association between mechanistic target of rapamycin pathway mutations and response to mechanistic target of rapamycin inhibitors in carcinoids. For LCNEC, preliminary data suggest that the two molecular subtypes might have a predictive value for chemotherapy response, but this observation needs to be validated in randomized prospective clinical trials. Finally, delta like Notch canonical ligand 3 inhibitors and immunotherapy may provide alternative options for patient-tailored therapy in LCNEC.
引用
- Derks JL, Leblay N, Lantuejoul S, et al. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. J Thorac Oncol. 2018. PMID: 29454048. doi:10.1016/j.jtho.2018.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。